SPPAM
HRTX icon

Summit Partners Public Asset Management’s Heron Therapeutics HRTX Stock Holding History

Summit Partners Public Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-325,000
Closed -$10.3M – 76
2018
Q3 		$10.3M Buy
+325,000
New +$12.1M 0.7% 52

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Summit Partners Public Asset Management's HRTX Position: Q4 2018 in Review

Summit Partners Public Asset Management sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 325,000 shares — an estimated $10.3M sold.

Summit Partners Public Asset Management first reported a position in HRTX in Q3 2018 and held it in 1 quarter. The position peaked at $10.3M in Q3 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

  • Summit Partners Public Asset Management reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 325,000 Heron Therapeutics shares in Q4 2018, an estimated $10.3M.
  • Summit Partners Public Asset Management first reported a position in Heron Therapeutics in Q3 2018 and held it in 1 quarter.
  • Summit Partners Public Asset Management's Heron Therapeutics position peaked at $10.3M in Q3 2018.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.